Q-omics provides the consensus-scored RPL36A profile across patient tissues and cancer cell-line models. RPL36A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL36A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RPL36A RNA expression shows 18,772 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where RPL36A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36A survival associations across molecular data types. RPL36A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36A RNA expression–survival associations across cancer types. High RPL36A expression shows unfavorable associations in KIRP, ACC, KIRC, HNSC and LIHC, but favorable associations in LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL36A RNA expression.
This table summarizes RPL36A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36A shows higher tumor expression in KIRC, LIHC, KIRP, COAD, LUAD and HNSC. The KIRC box plot shows higher RPL36A RNA expression in tumor versus normal tissue (log2 FC = +1.146, t-test p < 0.001).
This table shows molecular features associated with RPL36A in patient tissues and cancer cell lines. In patient samples, RPL36A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL36A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
